Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.53 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1707811 | 0.84 | SIGMAR1 (0.56) | KDM4EKMT2AKAT2BCHRNB2CHRNA4 | |
| SCHEMBL1623588 | 0.84 | ALDH1A1 (0.60) | KDM4E | |
| SCHEMBL5143427 | 0.84 | ALDH1A1 (0.60) | KDM4E | |
| SCHEMBL7005697 | 0.80 | KDM4E (0.75) | KDM4EKMT2ACHRNB2CHRNA4CHRNB4 | |
| SCHEMBL19049037 | 0.79 | CCR1 (0.55) | SIGMAR1 | |
| SCHEMBL20683848 | 0.78 | SCNN1A (0.50) | KDM4EKMT2AKAT2B | |
| SCHEMBL10523377 | 0.78 | KDM4E (0.61) | KDM4EKMT2ASIGMAR1 | |
| SCHEMBL28802088 | 0.78 | BCHE (0.51) | KDM4E | |
| SCHEMBL10523381 | 0.78 | ALDH1A1 (0.68) | KDM4EKMT2ASIGMAR1 | |
| SCHEMBL27430491 | 0.78 | SIGMAR1 (0.79) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750155-B2 | Pyrazinyl hydroxyacrylamide compounds having an inhibitory effect on the activity of histone deacetylase | ASTELLAS PHARMA INC. (JP) | 2010-07-06 | — | — | US | disclosed |
| US-20090054465-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLA PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054465-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | HDAC1, HDAC6, HDAC5 | KDM4E 450/4885KMT2A 67/4885KAT2B 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.